Fiche publication
Date publication
septembre 2025
Journal
Diabetes, obesity & metabolism
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DUVILLARD Laurence
,
Pr VERGES Bruno
,
Dr PAIS DE BARROS Jean-Paul
Tous les auteurs :
Béland-Bonenfant S, Denimal D, Pais-de-Barros JP, Choubley H, Rouland A, Simoneau I, Duvillard L, Aho-Glélé LS, Bouillet B, Petit JM, Vergès B
Lien Pubmed
Résumé
Patients with type 2 diabetes (T2D) are at an elevated risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), with a significant likelihood of progression to advanced liver fibrosis (AF)-a stage linked to adverse outcomes. Considering the critical role of lipids in the pathophysiology of MASLD and AF, we aimed to identify lipidomic biomarkers that could predict the development of AF in individuals with T2D.
Mots clés
diabetes complications, dyslipidaemia, fatty liver disease, type 2 diabetes
Référence
Diabetes Obes Metab. 2025 09 24;:
